LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER
Clinical trials for LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Dual-Action drug targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis early-stage study tests two related drugs in people with advanced hormone-receptor positive breast cancer that has spread or come back. The first drug (68Ga-R11228) helps doctors see tumors on a PET scan. The second drug (177Lu-R11228) delivers targeted radiation to kill can…
Matched conditions: LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Radionetics Oncology • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
New PET tracer aims to light up Hard-to-Find breast cancer spots
Diagnosis Recruiting nowThis early-phase study tests a new radioactive imaging agent called 68Ga-R10602 to see if it can find tumors in people with hormone receptor-positive breast cancer that has spread or come back. About 36 adults whose cancer no longer responds to hormone therapy will receive the ag…
Matched conditions: LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Radionetics Oncology • Aim: Diagnosis
Last updated May 07, 2026 18:40 UTC